Bioharvest Sciences vs Solesence
Solesence reported revenue of $62 million in fiscal 2025, 1.8 times Bioharvest Sciences' $34 million in fiscal 2025. Bioharvest Sciences' revenue grew 37.0% in its latest year, and Solesence's grew 18.6%. Bioharvest Sciences had an operating margin of -16.2%, against 4.2% at Solesence.
Side by side
| Bioharvest Sciences | Solesence | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $34M | $62M |
| Revenue growth | 37.0% | 18.6% |
| Revenue growth a year, last 5 years | — | 29.4% |
| Gross margin | 59.3% | 27.5% |
| Operating margin | −16.2% | 4.2% |
| Net margin | −32.3% | 4.5% |
| Free cash flow | −$10M | — |
| Free cash flow margin | −27.8% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | — | 11.6% |
| Last close | $1.32 | $1.48 |
| P/E at the last close | — | 29.6× |
| Insider trades, last 12 months | — | bought $4,785, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Bioharvest SciencesSolesence
Operating margin
Percent of revenue
Bioharvest SciencesSolesence
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Bioharvest SciencesSolesence
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Bioharvest Sciences and Solesence pages.